Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE000A3H2184
Wed, 21.12.2022       Epigenomics AG
DE000A3H2184

Epigenomics AG: Further raise of earnings guidance for the current fiscal year 2022 Berlin, Germany, December 21, 2022 - The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") again raises its earnings guidance for the current fiscal year 2022 due to lower costs, including, among others, lower study cos [ … ]
Technical analysis
To the publication
Wed, 21.12.2022       Epigenomics AG
DE000A3H2184

Epigenomics AG: Further raise of earnings guidance for the current fiscal year 2022 Berlin, Germany, December 21, 2022 - The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") again raises its earnings guidance for the current fiscal year 2022 due to lower costs, including, among others, lower study cos [ … ]
Technical analysis
To the publication
Wed, 14.12.2022       Epigenomics AG
DE000A3H2184

Epigenomics Releases Performance Data on Next Generation Test   Berlin, December 14, 2022- Epigenomics Inc, a wholly-owned subsidiary of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that today it has licensed certain patent and technology rights to biomarkers associated with colorectal cancer detection and  [ … ]
Technical analysis
To the publication
Wed, 14.12.2022       Epigenomics AG
DE000A3H2184

Epigenomics Releases Performance Data on Next Generation Test   Berlin, December 14, 2022- Epigenomics Inc, a wholly-owned subsidiary of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that today it has licensed certain patent and technology rights to biomarkers associated with colorectal cancer detection and  [ … ]
Technical analysis
To the publication
Mon, 19.09.2022       Epigenomics AG
DE000A3H2184

Publication of inside information pursuant to Article 17 MAR Epigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs Berlin, September 19, 2022 - The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") raises its earnings guidance for the c [ … ]
Technical analysis
To the publication
Mon, 19.09.2022       Epigenomics AG
DE000A3H2184

Publication of inside information pursuant to Article 17 MAR Epigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs Berlin, September 19, 2022 - The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") raises its earnings guidance for the c [ … ]
Technical analysis
To the publication
Fri, 09.09.2022       Epigenomics AG
DE000A3H2184

  Epigenomics AG: Capital reduction planned at a ratio of 4 : 1   Berlin, September 9, 2022 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") plans to propose to the extraordinary Shareholders' Meeting, which is to be convened on October 21, 2022 and conducted as a virtual general meeting without physical presence of  [ … ]
Technical analysis
To the publication
Fri, 09.09.2022       Epigenomics AG
DE000A3H2184

  Epigenomics AG: Capital reduction planned at a ratio of 4 : 1   Berlin, September 9, 2022 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") plans to propose to the extraordinary Shareholders' Meeting, which is to be convened on October 21, 2022 and conducted as a virtual general meeting without physical presence of  [ … ]
Technical analysis
To the publication
Fri, 20.08.2021       Epigenomics AG
DE000A3H2184

NOT TO BE PUBLISHED, DISSEMINATED OR PASSED ON TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA Publication of inside information pursuant to Article 17 MAR Reduction of principal amount of planned mandatory convertible bond to up to EUR 16.5 million and of conversion price to EUR 1.10 per share Berlin, German [ … ]
Technical analysis
To the publication
Tue, 17.08.2021       Epigenomics AG
DE000A3H2184

Epigenomics AG: Execution of a Biobank Sale Agreement and Update of Guidance Berlin, Germany, August 17, 2021 - Today Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") has entered into an agreement with New Horizon Health Limited (6606.HK) on the sale of certain non-essential biological samples. Gross proceeds from the sa [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 07.07.2024, Calendar Week 27, 189th day of the year, 177 days remaining until EoY.